Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Mature B-Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
B-Cell Neoplasm
Mature B-Cell Neoplasm

Hematologic Malignancy

Mature B-Cell Neoplasm

CI-CAN-00003258Explore in graph →

HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items

NCIt: C27910
DOID: 706

Overview
Statistics
Survival
Genomics20
Variants & evidence119
Drugs23
Trials6664
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (211)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 211 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
· Leukemia · 2017 · PMID 27568520 · validated civic_curation pubmed
Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.
· J Exp Clin Cancer Res · 2009 · PMID 19284554 · validated civic_curation pubmed
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
· Oncotarget · 2016 · PMID 27626698 · validated civic_curation pubmed
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
· J Clin Oncol · 2009 · PMID 19636007 · validated civic_curation pubmed
Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.
· Int J Clin Exp Med · 2015 · PMID 26221234 · validated civic_curation pubmed
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
· Clin Lymphoma Myeloma Leuk · 2014 · PMID 24997557 · validated civic_curation pubmed
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Showing 176–200 of 211 publications

← Previous
1
…
7
8
9
Next →

· Br J Haematol · 2013 · PMID 23480694 · validated civic_curation pubmed

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.

· Genes (Basel) · 2020 · PMID 32668764 · validated civic_curation pubmed

Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

· Eur J Haematol · 2014 · PMID 24330038 · validated civic_curation pubmed

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

· Blood · 2020 · PMID 32232486 · validated civic_curation pubmed

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

· Br J Haematol · 2019 · PMID 31234236 · validated civic_curation pubmed

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

· Cancer Sci · 2021 · PMID 33492746 · validated civic_curation pubmed

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.

· Oncogene · 2002 · PMID 12483530 · validated civic_curation pubmed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

· Cell · 2011 · PMID 21889194 · validated civic_curation pubmed

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

· PLoS One · 2011 · PMID 21494621 · validated civic_curation pubmed

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

· Haematologica · 2013 · PMID 23585524 · validated civic_curation pubmed

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

· Proc Natl Acad Sci U S A · 2012 · PMID 23236167 · validated civic_curation pubmed

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

· Cell Death Differ · 2014 · PMID 24013721 · validated civic_curation pubmed

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

· Mol Cancer Ther · 2010 · PMID 20124459 · validated civic_curation pubmed

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

· Nat Commun · 2019 · PMID 31160589 · validated civic_curation pubmed

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

· Am J Cancer Res · 2016 · PMID 27904766 · validated civic_curation pubmed

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

· Blood · 2000 · PMID 11050000 · validated civic_curation pubmed

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

· Blood · 2006 · PMID 16497971 · validated civic_curation pubmed

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

· Blood · 2006 · PMID 16690963 · validated civic_curation pubmed

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

· N Engl J Med · 2012 · PMID 22931316 · validated civic_curation pubmed